Dry Age Related Macular Degeneration

Overview of mild, moderate and severe dry AMD including drusen and geographic atrophy.

What are Drusen?

The hallmark of dry AMD is macular drusen (see photo). Drusen are made up of lipids, a type of fatty protein. They may be the result of a failure of the eye to dispose of waste products that are produced when the photoreceptors of the eye drop off older parts of the cell. There are several types of drusen with different levels of risk. Drusen can be small, hard and scattered far apart from each other. They are round and distinct. This type may not create vision problems for a long time and may not even be an indication of macular degeneration. Some drusen can become larger, softer and closer together. Their edges are less distinct. When they get to that stage, there is a greater risk for developing wet macular degeneration and more severe vision loss. They can also disrupt the layers of the retina and may lead to retinal pigment epithelium detachment (PED). Your doctor can see these drusen during a dilated eye exam, even if you are not aware of a vision change. That is one reason why regular eye exams are so important. If you have the larger, soft drusen, your doctor will probably want you to come into the office for check-ups more often. If they do lead to wet macular degeneration, early treatment is essential.

What is Geographic Atrophy?

Geographic atrophy occurs when the photoreceptors (seeing part of the retina) no longer works and the patient develops a blind spot or spot of poor vision in the macula (see photo). Geographic atrophy (GA) is considered the late stage of the dry form of Age-related Macular Degeneration (AMD). It only occurs in about 10 percent of dry AMD patients. GA is usually a sharply delineated round or oval area of hypopigmentation, or apparent absence of the retinal pigment epithelium (RPE), in which choroidal vessels are more visible than in surrounding areas The most common sequence of events leading to GA is the progression of a large drusen to hyperpigmentation, followed by regression of the drusen, hypopigmentation and ultimately RPE cell death, with development of an atrophic area of retina and underlying choriocapillaris, sometimes preceded by the appearance of refractile deposits. This usually takes more than 5 years. Less frequently, GA can follow a drusenoid RPE detachment, regression of a CNV membrane or a RPE rupture. As other forms of late AMD, GA tends to be bilateral (over 50% of cases) and there is high symmetry between eyes for total atrophic area, presence of peripapillary atrophy and enlargement rate. GA often first develops surrounding the fovea, sparing the central area.

What is Progressive Geographic Atrophy?

Geographic atrophy can progress and lead to vision loss. When people with dry AMD lose vision, it is almost always from geographic atrophy. The animated image with this text shows growing geographic atrophy over 3 years in an 86 year old patient. This person is fortunate to have good vision because the dark areas of geographic atrophy are not yet affecting the central vision. Given the progression, the central vision will likely be affected within about 10 years. The images are fundus autofluorescent images that are useful for following geographic atrophy because the atrophy shows up as well delineated dark spots.

What is Pattern Dystrophy?

Pattern dystrophy is a type of dry age-related macular degeneration that involves mostly the very center of the macula. There are several types of pattern dystrophy. The image with this text is of a patient with adult vitelliform macular dystrophy. The image shows the buildup of abnormal deposits under the retina in the center of the macula. Unlike typical dry macular degeneration where the buildup of material is below the retinal pigment epithelium, in pattern dystrophy, the buildup of material is above the pigment epithelium and directly beneath the retina (see asterisks on image). Pattern dysrophy is autosomal dominant, usually presents at a younger age than typical dry AMD, and usually does not progress to wet AMD.

Pattern Dystrophy

What about Diet?

Patients who consume fruits and vegetables have the lowest rates of macular degeneration development. Lutein, a carotenoid pigment found exclusively in fruit and vegetables, serves as the primary protector of the eye. Lutein accumulates in the macula and likely blocks the damage caused by sunlight, one proposed cause of AMD. Fruits and vegetables are also high in antioxidant vitamins such as Beta- carotene, Vitamin E, and Vitamin C. Green leafy vegetables and other colorful foods like kiwi, squash, red grapes, and corn are good sources of Lutein. Other dietary habits have been shown to increase the risk of AMD. Individuals with a higher percentage of vegetable, monounsaturated, and polyunsaturated fats in their diet have higher rates of Wet AMD development. Diets rich in Omega 3 fatty acids reduce the risk of vision loss. These are found naturally in cold-water fish such as salmon and tuna, and in flaxseeds and flaxseed oil. Two servings of fish per week are adequate.

What about Vitamins?

The Age-Related Eye Disease Study 2 showed that among people at high risk for developing late-stage, or wet, macular degeneration (such as those who have large amounts of drusen or who have significant vision loss in at least one eye), taking a dietary supplement of vitamin C, vitamin E, lutein and zeaxanthin, along with zinc, lowered the risk of macular degeneration progressing to advanced stages by at least 25 percent. The supplements did not appear to provide a benefit for people with minimal macular degeneration or people without evidence of the disease during the course of the study. These vitamins contain a mixture of Vitamins C and E, Lutein, Zeaxanthin, Zing and Copper. Another large study in women showed a benefit from taking folic acid and vitamins B6 and B12. It is very important to remember that vitamin supplements are not a cure for macular degeneration, nor will they give you back vision that you may have already lost from the disease. However, these supplements do play a key role in helping some people at high risk for developing advanced (wet) AMD to maintain their vision, or slow down the progression of the disease.

What about Amsler Grid?

One of the first signs of macular degeneration can be wavy, broken or distorted lines OR a blurred or missing area of vision. The Amsler Grid can help you spot these early. Early detection of wet AMD is critical because laser treatment, when indicated, is most successful when performed before damage occurs. Since dry AMD can lead to development of wet AMD, most patients should use the Amsler Grid. Check with your eye doctor to find out how often you should use this test. Wear your reading glasses, if you normally use them and sit about 14 inches away from the screen. Check one eye at a time. Cover the eye you are not testing. Focus on the dark dot in the center of the grid. While looking at this dot, you still should be aware of the lines of the grid. Notice if any of the lines are distorted or broken or if there are blurred areas.

Download Amsler Grid

Dry Macular Degeneration NEWS

Below are current articles from a Google News Feed on Dry Macular Degeneration

What is age-related macular degeneration?  Times Herald-Record

February is Age-Related Macular Degeneration (AMD) Month.Age-related macular degeneration is deterioration of the retina and deeper layers of the eye that ...

7 Tips to Stop Macular Degeneration  Healthline

Macular degeneration is one of the leading causes of blindness in the United States. Here's how to keep your vision safe while enjoying the sun this spring ...

Macular degeneration treatment market size worth around US $11.4 billion by 2026: Acumen Research and Consulting  GlobeNewswire

LOS ANGELES, March 16, 2019 (GLOBE NEWSWIRE) -- The global macular degeneration treatment market size is anticipated to value USD 11.4 billion by ...

Seeing clearly: Know your risk for macular degeneration  Baylor College of Medicine News

More than 60 million Americans are estimated to be at high risk for vision loss. However, according to the CDC, only half of those at risk have visited an eye ...

Bowie woman's increasing blindness from macular degeneration depicted in film  Times Record News

Macular degeneration is the leading cause of vision loss affecting more than 10 million Americans, more than cataracts and glaucoma combined.

Théa and OliX Announce Collaboration to Develop RNAi Therapies for the Treatment of AMD  PRNewswire

License and Collaboration Agreement was signed between OliX and Théa for OLX301A program, a novel treatment for dry and wet age-related macular ...

First patient dosed with gene therapy to treat AMD  EPM Magazine

The first patient in the UK has been successfully dosed with a novel gene therapy developed to treat age-related macular degeneration (AMD).

LumiThera receives $2.5 million grant to study dry AMD treatment option  Healio

LumiThera has received a $2.5 million small business innovative research phase II grant from the National Institute of Health and the National Eye Institute to ...

Dr Joshua Dunaief MD, Renowned Age-Related Macular Degeneration Clinician and Researcher, Joins Mperia Therapeutics Inc. Clinical Advisory Board  BioSpace

MONTREAL--(BUSINESS WIRE)-- Dr. Joshua Dunaief, PhD, MD, the Adele Niessen Professor of Ophthalmology, Scheie Eye Institute, University of ...

7 Macular Degeneration Risk Factors You Can Control—and 4 You Can't  Reader's Digest

Your chances of getting this top cause of vision loss in people age 60 and older—depends on both your genetics and your lifestyle.

Théa and OliX partner on RNAi therapies for AMD  The Pharma Letter

South Korean RNAi therapeutics developer OliX Pharmaceuticals (Kosdaq: 226950) has signed a license and collaboration agreement with Théa Open ...

UK woman has first gene therapy operation for dry AMD  BioNews

An 80-year-old woman from Oxford – Janet Osborne – has undergone the world's first gene therapy operation to target the root cause of age-related macular ...

Pixium Vision highlights conclusions of its KOL Meeting: Experts confirm PRIMA's promises and potential to treat dry-AMD  Associated Press

This *content* is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation.

LumiThera Receives Notice of Award for $2.5 Million National Eye Institute Grant to Support US Multi-Center Clinical Trial for Treating Dry Age-Related Macular Degeneration  PRNewswire

SEATTLE, Feb. 26, 2019 /PRNewswire/ -- LumiThera Inc., a commercial stage medical device company creating a photobiomodulation (PBM) treatment for ...

BioTime to Present New Data From OpRegen® and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019)  Associated Press

This *content* is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation.

Anti-VEGF Treatment Not Linked to Increased Risk of Stroke, Myocardial Infarction or Death  MD Magazine

The investigators also examined patients who had 3 or more injections in the year prior to their cardiac event.

How to prevent macular degeneration - The Listener  Noted

Zinc, carotenoids and vitamins can help with macular degeneration, but it's all in the formula.

What Is the Difference Between Wet or Dry Macular Degeneration?  University of Michigan Health System News

Dry macular degeneration occurs when cells of the macula begin to thin and break down. It is characterized by drusen buildup and typically worsens over time.

Pixium Vision to host KOL Meeting on March 5, 2019 in Paris  GlobeNewswire

Paris, France. February 28, 2019 – 7.00 AM CET - Pixium Vision (FR0011950641 - PIX), a bioelectronics company developing innovative bionic vision systems ...

Age Related Macular Degeneration 2019 Trends, Statistics, Size, Share, Key Companies, Growth, And Regional Forecast To 2023 - Press Release  Digital Journal

The Report on the “Age Related Macular Degeneration Market” of Market Research Future Comprises of Extensive Primary Research along with the Detailed ...

LumiThera Announces an Agreement with Andrec Corporation SA to Distribute the Valeda Light Delivery System in Colombia and Several Latin American Countries  BioSpace

Published: Mar 07, 2019. SEATTLE, March 7, 2019 /PRNewswire/ -- LumiThera Inc., a commercial-stage medical device company focused on developing ...

Wet Age Related Macular Degeneration (AMD) Market 2025 includes Trends, Growth Factors, End-Users, Top Key Players and Revenue  Current News Magazine

Wet Age Related Macular Degeneration (AMD) Market Report cover definite aggressive standpoint including the piece of the overall industry and profiles of the ...

World’s first gene therapy operation to halt common form of vision loss  Tech Explorist

In an extraordinary milestone procedure, scientists in the UK have performed the first gene therapy operation aimed at stopping progression of the most common ...

What you need to know about wet macular degeneration  Medical Xpress

Millions of people deal with age-related macular degeneration as they get older, but many don't understand the difference between types of the condition or ...

Breakthrough in identifying new genes in age-related macular degeneration, the leading cause of blindness  Medical Xpress

Fight for Sight funded research published this week in Clinical Epigenetics, has identified new genes linked to the development of age-related macular ...

Take steps to prevent vision loss from macular degeneration  Buffalo News

By Judith Whitehead – Contributing Writer Age-related macular degeneration is the leading cause of blindness among older Americans but treatments have ...

Age-related Macular Degeneration Market 2019 – Bayer HealthCare, F. Hoffmann-La Roche, Novartis, Regeneron Pharmaceuticals, Alcon  Market Reports

Recent study titled, “Age-related Macular Degeneration Market“ which covers detailed statistical analysis and enlightens market dynamics and trends that ...

Age-Related Macular Degeneration: 5 Things to Know  Medscape

A guide to the latest on this chronic disease, from emerging treatments to the risk factors to be on the lookout for.

Trial will be first in US of Nobel-winning stem cell technique  STAT

Curing diabetes with stem cells? Everyone knew that would be hard. Parkinson's disease? Harder. Alzheimer's? Probably impossible. But age-related macular ...

LumiThera Receives Seattle Business Magazine 2019 Leaders in Health Care Award for Achievement in Medical Technology  BioSpace

SEATTLE, March 12, 2019 /PRNewswire/ -- LumiThera Inc., a commercial stage medical device company creating a photobiomodulation (PBM) treatment for ...

Human Trials Could Begin for Macular Degeneration Stem Cell Therapy  MD Magazine

FDA trial approval would make this trial the first ever to test a stem cell-based therapy derived from induced pluripotent stem cells for treating any disease.

Aged-related macular degeneration is incurable but preventable  New Jersey 101.5 FM Radio

Aged-related macular degeneration is the top cause of blindness in people age 50 and older.

Be aware of age-related macular degeneration  thebellvillestar.com

COLUMBUS — Age-related macular degeneration (AMD), is a leading cause of vision loss for Americans age 50 and older. The eye disease causes damage to.

Stem Cell Therapy Shows Early Promise Against Macular Degeneration  HealthDay

THURSDAY, Jan. 17, 2019 (HealthDay News) -- Age-related macular degeneration is the leading cause of vision loss in seniors, and existing treatments are few ...

Stem Cell Therapy Patch for Macular Degeneration Sees the Light of Day  Genetic Engineering & Biotechnology News

If approved, the first ever clinical trail to test a stem cell-based therapy may provide a cure for age-related macular degeneration.

Reviewing Kodiak Sciences Inc. (KOD)'s and Rigel Pharmaceuticals Inc. (NASDAQ:RIGL)'s results  Thе Mоnіtоr

Kodiak Sciences Inc. (NASDAQ:KOD) and Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) have been rivals in the Biotechnology for quite some time. Below is a ...

BioTime Announces Closing of Acquisition of Asterias Biotherapeutics Creating Leading Cell Therapy Company  Business Wire

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American and TASE: BTX), today announced the closing of its previously reported acquisition of ...

Revolutionary eye drops to treat age-related macular degeneration  Drug Target Review

Revolutionary eye drops to treat age-related macular degeneration - developing an eye drop that could revolutionise treatment for AMD.

Comparison of Ophthotech Corporation (OPHT) and MorphoSys AG (NASDAQ:MOR)  Lives Advice

As Biotechnology companies, Ophthotech Corporation (NASDAQ:OPHT) and MorphoSys AG (NASDAQ:MOR) are our subject to compare. And more specifically ...

7 Healthy Habits to Help Prevent Macular Degeneration  University of Michigan Health System News

AMD affects the eyesight of millions. A Michigan Medicine specialist offers easy ways to help slow or prevent the disease.

Blindness: Macular Degeneration Implant Treatment  Healthline

Researchers say the implant process could eventually be a treatment for the loss of eyesight experienced by millions as they grow older.

AMD Monitoring Comes Home: The Promise of Remote Tech  Medscape

Age-related macular degeneration (AMD) is the leading cause of severe vision loss in older Americans. AMD is a degenerative disease that affects the macula, ...

The eyes have it: Seven tips for maintaining vision  Dolphin

FALLS CHURCH, Va. - Eyes may be the window to the soul, as William Shakespeare reportedly said, but in the military, eyesight is essential to remain fit for duty ...

Hope for new treatments buoys macular degeneration patients  The Boston Globe

Scientists are experimenting with dozens of new treatments, including about 20 in clinical trials, to combat an eye disease that afflicts more than 9 million ...

Ask the Expert: Macular degeneration can lead to difficulty reading, recognizing faces and performing other fine tasks  Baltimore Sun

Macular degeneration is a disease of the eye that doesn't lead to total blindness, but in its advanced stages can cause blind areas. This can make it hard for ...

Fewer Injections With New Wet Macular Degeneration Therapies  Medscape

New treatments in development — including gene therapy — will likely mean fewer injections for patients with neovascular age-related macular degeneration, ...

Researchers are one step closer to developing eye drops to treat age-related macular degeneration  Medical Xpress

Scientists at the University of Birmingham are one step closer to developing an eye drop that could revolutionise treatment for age-related macular degeneration ...

How to spot age-related macular degeneration | Life and style  The Guardian

Every day in the UK, nearly 200 people develop a condition that can lead to visual impairment or even blindness. How do you identify the symptoms and what's ...

Special Section: Spotlight on Independent Medical Providers  zionsvillemonthlymagazine.com

Special Section: Spotlight on Independent Medical Providers. Read about these local independent practitioners that have chosen to remain independent.

OpRegen shows positive phase 1/2a study results for dry AMD  Healio

CHICAGO — OpRegen, a retinal pigment epithelium cell therapy transplant for dry age-related macular degeneration, has shown signs of improving the retina ...

Ionis Pharmaceuticals Inc. (IONS) and Ophthotech Corporation (NASDAQ:OPHT) Comparison side by side  Thе Mоnіtоr

Both Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and Ophthotech Corporation (NASDAQ:OPHT) compete on a level playing field in the Biotechnology industry.

Drug and Device News March 2019  P&T Community

Approvals, new indications and formulations, and safety issues.

Age-Related Macular Degeneration Drug Combo Scrapped Despite Safe Profile  Specialty Pharmacy Times

Ophthotech Corp. said it won't move forward with further clinical trials of its complement factor C5 inhibitor for the treatment of wet age-related macular ...

This Retinal Implant Lets Visually-Impaired Patients See Patterns  Labiotech.eu

An electronic chip from French company Pixium Vision, inserted behind the retina to treat age-related macular degeneration, has shown excellent results in a ...

Ophthotech Reports Fourth Quarter and Full Year 2018 Financial and Operating Results  Business Wire

Ophthotech announced financial and operating results for the fourth quarter and full year ended December 31, 2018, and provided a business update.

Tiny eye device could make big difference for millions with blinding disease  Philly.com

Wills Eye Hospital has helped test an implantable delivery system for a widely used medication for age-related macular degeneration.

Gemini to initiate CLARITY dry AMD disease registry and study  Healio

Gemini Therapeutics announced a disease registry and natural history study to identify and characterize disease progression in patients with non-central ...

Reviewing Ophthotech Corporation (OPHT)'s and Acasti Pharma Inc. (NASDAQ:ACST)'s results  The Moveefy

Ophthotech Corporation (NASDAQ:OPHT) and Acasti Pharma Inc. (NASDAQ:ACST), both competing one another are Biotechnology companies. We will ...

Wills Eye Hospital releases new implant to help macular degeneration  KYW Newsradio 1060

PHILADELPHIA (KYW Newsradio) — There may soon be a way to preserve your vision with a lot less hassle.

BioTime, Orbit Biomedical to collaborate on OpRegen subretinal delivery for dry AMD  Healio

BioTime has entered into a research and option agreement with Orbit Biomedical regarding technology to deliver OpRegen to treat dry age-related macular ...

Eye Health: Reduce Your Risk of Macular Degeneration  Newsmax

Age-related macular degeneration (AMD) is an incurable eye disease that affects millions of older Americans, but there are a number of things you can do to ...

Metformin for Macular Degeneration  Healthline

The popular diabetes medication, metformin, may soon be used not just to regulate blood sugar but to protect against a common form of blindness, called ...

Has UVa Found a Cure for Macular Degeneration?  WMRA Public Radio

Macular degeneration may not get as much attention as Alzheimer's disease or breast cancer, but nearly one-third of people over 80 are affected by it. One.

Tie2 activation promotes choriocapillary regeneration for alleviating neovascular age-related macular degeneration  Science Advances

Choriocapillary loss is a major cause of neovascular age-related macular degeneration (NV-AMD). Although vascular endothelial growth factor (VEGF) blockade ...

Reviewing BioTime Inc. (BTX)'s and Coherus BioSciences Inc. (NASDAQ:CHRS)'s results  Thе Mоnіtоr

As Biotechnology businesses, BioTime Inc. (NYSEAMERICAN:BTX) and Coherus BioSciences Inc. (NASDAQ:CHRS), are affected by contrast. This especially ...

EyeMax Mono IOL shows promise in patients with macular disease  Healio

Visual acuity improved in patients with geographic atrophy who underwent cataract surgery and implantation of a novel monofocal IOL in the capsular bag, ...

Early Promise for Eye Implant to Fight Macular Degeneration  HealthDay

A new stem cell transplant might help preserve or even restore vision being lost to the dry form of age-related macular degeneration, a new pilot clinical trial has ...

Is Selling Catalyst Biosciences, Inc. (CBIO) Here a Winning Strategy? | Thorold News  Thorold News

The stock of Catalyst Biosciences, Inc. (NASDAQ:CBIO) is a huge mover today! The stock decreased 5.98% or $0.58 during the last trading session, reaching.

Unafraid to Ask More: Macular Degeneration  University of Virginia

A team of UVA researchers set out to cure macular degeneration. What they discovered may protect people from this disease – as well as many other ...

Reviewing Sophiris Bio Inc. (SPHS)'s and Ophthotech Corporation (NASDAQ:OPHT)'s results  The FinExaminer

Sophiris Bio Inc. (NASDAQ:SPHS) and Ophthotech Corporation (NASDAQ:OPHT), both competing one another are Biotechnology companies. We will compare ...

World's first gene therapy operation for common cause of sight loss  Medical Xpress

Researchers in Oxford have carried out the world's first gene therapy operation to tackle the root cause of age-related macular degeneration (AMD), the UK's ...

Change Within the Eye May Be Early Warning for Macular Degeneration  HealthDay

FRIDAY, Nov. 9, 2018 (HealthDay News) -- Age-related eye disease is a worldwide problem that costs people not only their vision, but also hundreds of billions ...

Drug Slows Atrophy in Dry AMD | Medpage Today  MedPage Today

No vision improvement with complement C3 inhibitor.

Gyroscope's gene therapy given to first dry AMD patient  PMLiVE

UK biotech Gyroscope Therapeutics could have a mass market product on its hands if its new gene therapy for one of the most common form of blindness proves ...

Reviewing Ophthotech Corporation (OPHT)'s and Tocagen Inc. (NASDAQ:TOCA)'s results  The Moveefy

As Biotechnology companies, Ophthotech Corporation (NASDAQ:OPHT) and Tocagen Inc. (NASDAQ:TOCA) are our subject to compare. And more specifically ...

Implant Poised to Transform Macular Degeneration Treatment  Medscape

A system that delivers ranibizumab without injections could be a turning point for patients with neovascular age-related macular degeneration, results from the ...

5 questions: Breakthroughs in treatment for a common cause of vision loss among U.S. seniors  Philly.com

The standard treatment has been regular injections to the eyeball. So, not surprisingly, an active area of research has focused on finding alternatives, including ...

Arbutus Biopharma Corporation (ABUS)'s Financial Results Comparing With Ophthotech Corporation (NASDAQ:OPHT)  The FinHeadLines

Both Arbutus Biopharma Corporation (NASDAQ:ABUS) and Ophthotech Corporation (NASDAQ:OPHT) are each other's competitor in the Biotechnology industry.

New genes associated with the leading cause of blindness  Science Daily

A new study identifies genes associated with Age-related Macular Degeneration (AMD) that could represent new targets for future drug development.

UVA Doctor States Possible Solution to Stop Macular Degeneration  NBC 29 News

A University of Virginia doctor thinks he could have a cure for a common type of blindness.

Stealth BioTherapeutics Granted Fast Track Designation for Elamipretide for the Treatment of Dry Age-Related Macular Degeneration with Geographic Atrophy  PRNewswire

BOSTON, Dec. 10, 2018 /PRNewswire/ -- Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat ...

BioTime, Inc. (BTX) Expected to Announce Quarterly Sales of $740,000.00  Modern Readers

Wall Street analysts expect that BioTime, Inc. (NASDAQ:BTX) will report $740000.00 in sales for the current fiscal quarter, according to Zacks Investment ...

Comparing of Kodiak Sciences Inc. (KOD) and Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)  The FinHeadLines

This is a contrast between Kodiak Sciences Inc. (NASDAQ:KOD) and Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) based on their institutional ...

Drug Pipeline for Macular Degeneration in Focus at AAO  Medscape

Updates from phase 3 trials of VEGF inhibitors for neovascular age-related macular degeneration, and a novel genetic treatment, will be highlighted at the ...

Zimura/Lucentis Combo Safe, But Company Decides Not to Move Forward  MD Magazine

Ophthotech says it's sidelining its Zimura/Lucentis program despite positive phase 2a results.

Pixium Vision announces its PRIMA chip successfully met interim study endpoints for dry AMD  GlobeNewswire

Pixium Vision announces its wireless PRIMA chip successfully met the interim study endpoints for dry Age-related Macular Degeneration. Implant is well ...

Eyeing Improvement: Fine-Tuning Anti-VEGF for Macular Degeneration  MD Magazine

Anti-VEGF injection therapy is the proven choice of care for AMD and DME. Still, concerns about dosing, costs, and convenience persist into 2019.

Calcifications in the eye increase risk for progression to advanced AMD by more than six times  Medical Xpress

Calcified nodules in the retina are associated with progression to late stages of age-related macular degeneration (AMD). Experts from Queen's University ...

Patient Voices: Macular Degeneration  New York Times

Five men and women speak about their lives with progressive vision loss.

Implanting stem cell 'patch' can restore vision  Futurity: Research News

Clinical trial results show that a stem cell patch can treat sudden, severe sight loss due to a form of macular degeneration.

Retinal implant designed to replace support cells damaged by dry age-related macular degeneration  Science Daily

Researchers have published preliminary results of a first-in-human clinical trial for dry age-related macular degeneration (AMD). Four patients received implants ...

Kodiak Sciences Files for IPO to Fund Global AMD Eye-Drug Studies  Xconomy

Many patients with the more severe form of age-related macular degeneration, a type of vision loss, have trouble with the standard treatment---a.

A focus on Age-related Macular Degeneration this World Braille Day  Lexology

World Braille Day is observed every year on 4 January to celebrate the invention of braille. Braille is a tactile reading and writing system…

Ionis may have found a home for dry AMD drug with Roche in $760M deal  FierceBiotech

Ionis signed on with Roche to help develop its RNA-based drug for advanced dry AMD and other diseases, in a deal worth up to $760 million, after being ...

Macular Degeneration: Stem Cells Restore Sight in Small Study  Medscape

Doctors in the UK say they have taken an important step towards treating a common form of blindness – wet age-related macular degeneration (AMD).

Mediterranean diet prevents a leading cause of blindness, study suggests: Research shows we can all eat our way to better eye health  Science Daily

Evidence is mounting that a poor diet plays an important role in the development of age-related macular degeneration (AMD), a leading cause of blindness in ...

Antioxidants improve visual function in nonadvanced AMD  Healio

Supplementation with macular carotenoids in two formulations, containing and not containing mesozeaxanthin, in combination with coantioxidants, showed ...

Researchers identify new genes linked to age-related macular degeneration  PharmaTimes

Fight for Sight has announced a breakthrough in identifying new genes in age-related macular degeneration, the leading cause of blindness. - News ...

Comparing of Ophthotech Corporation (OPHT) and Incyte Corporation (NASDAQ:INCY)  The FinHeadLines

Ophthotech Corporation (NASDAQ:OPHT) and Incyte Corporation (NASDAQ:INCY) are two firms in the Biotechnology that compete against each other. Below is ...

Aerie Pharmaceuticals Inc (AERI) Q4 2018 Earnings Conference Call Transcript  The Motley Fool

AERI earnings call for the period ending December 31, 2018.

» Load more

What about Resources?

Dr. Pautler's Blog
American Academy of Ophthalmology
MedlinePlus
National Institutes of Health
  • ARMD
    NIH's SeniorHealth website covers the topic of Age-Related Macular Degeneration
National Eye Institute
American Foundation for the Blind - Senior Site
  • Macular Degeneration
    Basic information about AMD and low vision; includes a self-test using an Amsler Grid
Journal of the American Medical Association (JAMA)
WebMD
LightHouse International
  • Macular Degeneration
    Provides a general overview of the basics of AMD, and a simulation showing a scene as it might be viewed by a person with AMD
Prevent Blindness America